Voyager Therapeutics (VYGR) Accumulated Expenses (2014 - 2026)
Voyager Therapeutics (VYGR) posted Accumulated Expenses of $7.0 million for Q1 2026, down 23.31% sequentially from $9.1 million in Q4 2025, and down 22.99% YoY from $9.1 million in Q1 2025.
Voyager Therapeutics (VYGR) Accumulated Expenses (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Accumulated Expenses for 13 years, with the latest figure at $7.0 million in Q1 2026.
- Quarterly Accumulated Expenses fell 22.99% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (down 22.99% YoY) and the FY2025 annual result came in at $9.1 million, up 34.64% from the prior year.
- Accumulated Expenses eased to $7.0 million in Q1 2026 per VYGR's latest filing, from $9.1 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $16.8 million in Q4 2023 and troughed at $2.2 million in Q1 2024.
- A 5-year average of $7.7 million and a median of $7.0 million in 2026 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2025: Accumulated Expenses sank 74.45% in 2022, then soared 302.71% in 2025.
- Over 5 years, Accumulated Expenses stood at $7.8 million in 2022, then jumped by 115.24% to $16.8 million in 2023, then plunged by 59.86% to $6.8 million in 2024, then soared by 34.64% to $9.1 million in 2025, then slipped by 23.31% to $7.0 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $7.0 million, $9.1 million, and $15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Voyager Therapeutics | 205.86 Mn | 89.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.95 Mn |
| Mar 31, 2026 | 6.97 Mn |
| Dec 31, 2025 | 9.09 Mn |
| Sep 30, 2025 | 14.95 Mn |
| Jun 30, 2025 | 12.03 Mn |
| Mar 31, 2025 | 9.05 Mn |
| Dec 31, 2024 | 6.75 Mn |
| Sep 30, 2024 | 5.93 Mn |
| Jun 30, 2024 | 10.27 Mn |
| Mar 31, 2024 | 2.25 Mn |
| Dec 31, 2023 | 16.82 Mn |
| Sep 30, 2023 | 4.81 Mn |
| Jun 30, 2023 | 3.73 Mn |
| Mar 31, 2023 | 2.49 Mn |
| Dec 31, 2022 | 7.82 Mn |
| Sep 30, 2022 | 12.53 Mn |
| Jun 30, 2022 | 2.80 Mn |
| Mar 31, 2022 | 3.15 Mn |
| Dec 31, 2021 | 5.02 Mn |
| Sep 30, 2021 | 11.32 Mn |